Samaritan Pharmaceuticals Inc- HIV Adjunct Treatment Phase II Results

[Guest guest]

Press Release: Samaritan Announces Positive Preliminary Results in a

Phase IIb Study For Its Oral HIV Entry Inhibitor

July 20, 2007

Samaritan Announces Positive Preliminary Results in a Phase IIb Study

For Its Novel Oral HIV Entry Inhibitor

SP01A Being Developed as an Adjunct Treatment for 'HIV Drug

Resistance' Has Demonstrated Efficacy in Three Phase II Clinical Trials

LAS VEGAS, July 20, 2007 -- Samaritan Pharmaceuticals Inc. (AMEX:LIV),

a developer of innovative drugs, is pleased to announce its novel oral

HIV entry inhibitor SP-01A, being developed as an adjunct treatment

for HIV drug resistance, has received positive preliminary results in

a Phase IIb 28-Day Monotherapy Study.

Adjunctive therapy is another HIV treatment used together with the

primary antiretroviral treatment. Its purpose is to assist the primary

treatment to make it work even better or where the primary

antiretroviral treatment alone is inadequate. When Samaritan studied

SP-01A as an adjunctive therapy in its Phase II " proof of concept "

clinical trial, the results were statistically significant and

promising. However, when Samaritan submitted SP-01A to the FDA as an

adjunctive therapy, the FDA requested that we also explore SP-01A's

efficacy alone as an antiretroviral in monotherapy studies.

To date, SP01A has demonstrated efficacy in three Phase II clinical

trials,

1. SP-01A in a PIb/PIIa clinical trial study, as an adjunct to triple

antiretroviral therapy, demonstrated a significant 1.342 log10

difference in viral load.

2. SP-01A alone in a PIIb 10 Day HIV Monotherapy Study demonstrated a

0.4 log10 difference in viral load.

3. Preliminary Results of SP-01A alone in a PIIb 28-Day HIV

Monotherapy Trial shows a 0.5 log10 difference in viral load.

The Monotherapy Study was a Phase II double-blind, placebo controlled,

multi-dose study in treatment-experienced HIV patients to assess

SP01A's safety and effect on viral load in HIV positive individuals

with evidence of an increasing viral load. Essentially, viral load

measures how many copies of the HIV virus there are in a unit of the

individual's blood. Viral load changes are often described as " log "

changes. The viral load test is one of several great tools for doctors

to assess the efficiency and health of a person's immune system.

In the preliminary finding SP01A showed positive results in that

subjects taking SP-01A showed a reduction in the amount of viral

infection in their blood, with a dose dependent relationship in effect

on viral load with a positive 0.5 log10 difference in viral load

between the high dose group (800mg/day) and the low dose group

(200mg/day).

In addition, there was also a dose dependent relationship in the

number of subjects who had a reduction in viral load with the high

dose group showing the most difference as compared to the low dose

group (50% vs. 10%, respectively).

Samaritan and its SP-01A collaborative partner Pharmaplaz, Ireland,

plan to submit finalized data to the U.S. Food and Drug Administration

and the European Medicines Agency.

Dr. Greeson, CEO of Samaritan Pharmaceuticals stated, " We are very

encouraged by these results. These results are not only positive for

SP-01A as an adjunctive therapy; it also suggests to us that SP-01A

might have potential alone as an entry inhibitor coupled with just one

" killer " antiretroviral drug. "

HIV 28-day Monotherapy Clinical Trial Highlights:

* The study enrolled 43 evaluable patients in placebo and 3 active

dose groups. * The active treatment groups were 200mg (200mg QD),

400mg (200mg BID), and 800mg (400mg BID) of SP01A. * Mean change in

viral load for the active arms, as measured from Baseline to Day 11,

showed an increase of 0.3 log10 copies/ml for the 200mg/day dose

group, an increase of 0.1 log10 copies/ml for the 400mg/day dose

group, and a decrease of 0.2 log10 copies/ml for the 800mg/day dose

group. * The percentage of subjects having a reduction in viral load

over the 28 day monotherapy treatment period were 10% for the

200mg/day group, 42% for the 400mg/day group, and 50% for the

800mg/day group.

Samaritan Pharmaceuticals: " Transforming Today's Science Into

Tomorrow's Cures... "

Samaritan Pharmaceuticals is a life science company focused on

commercializing innovative drugs to relieve the suffering of patients

with Alzheimer's, Cancer, Heart disease, and Infectious disease.

Website, http://www.samaritanpharma.com.